Ferrum Hausmann

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferrum Hausmann

Property	Description
Active ingredient	Iron (III) Hydroxide Dextran Complex
Form	Solution for Injection (Parenteral)
Pharmacological class	Antianemic Agent / Iron Replacement Therapy
Common use	Treatment of severe Iron Deficiency Anemia (IDA)
Origin	Synthetic Complex

Ferrum Hausmann is an antianemic agent formulated as an injectable solution designed to quickly and reliably replenish iron stores in the body. The active pharmaceutical ingredient (API) is Iron (III) Hydroxide Dextran Complex, commonly referred to as iron dextran. This medication belongs to the antianemic pharmacological class and is distinctly different from oral iron supplements because it is administered parenterally, bypassing the digestive system entirely.

Composition and Origin: Unique Iron Complex

Iron Dextran is a synthetic compound composed of iron (III) hydroxide particles stabilized by a carrier molecule called dextran. This complex is engineered in a laboratory setting to create a non-ionic structure that safely delivers a high dose of iron. This specific formulation is clinically recognized for its stability and slow release kinetics, which minimize the risk of toxicity associated with unbound iron. The dextran component acts as a shield, allowing for controlled uptake by the body's iron transport system.

General Purpose and Patient Group

The primary purpose of Iron Dextran is to rapidly correct severe iron deficiency anemia in individuals who cannot tolerate or adequately absorb iron taken by mouth. It is used to quickly restore the body's iron levels, which are critical for forming hemoglobin. This treatment is often utilized in patients with chronic conditions, such as inflammatory bowel disease or chronic kidney disease, where oral iron is either ineffective or contraindicated. The ability to deliver iron directly into the circulation makes it a recognized intervention for situations where a swift and substantial increase in iron stores is medically necessary.

Regulatory References

MedlinePlus Drug Information

What side effects are possible with Ferrum Hausmann?

Possible side effects and safety information

The safety profile of injectable iron (Iron (III) Hydroxide Dextran Complex) is classified by regulatory authorities based on the frequency and type of adverse reactions observed in clinical use.

Serious and Clinically Significant Reactions

The most serious safety concern documented in regulatory labeling is the risk of anaphylactic-type reactions, which are classified as rare but have been reported to be life-threatening. These reactions can involve cardiovascular collapse and often occur most frequently within the first several minutes of administration. Official safety documentation requires that the treatment only be administered in settings where resuscitation techniques and trained personnel are immediately available.

Common Adverse Reactions and Systemic Effects

Adverse effects listed as common in prescribing information include local reactions at the injection site, such as pain, swelling, and inflammation. Systemic reactions frequently reported across different organ classes include nausea, vomiting, backache, chest pain, dizziness, and pruritus (itching).

Other systemic effects may be delayed, sometimes appearing one to two days after administration, and include symptoms such as fever, chills, joint pain (arthralgia), and muscle pain (myalgia).

Safety Restrictions and Special Populations

Regulatory documents establish specific limitations for use. The medication should not be used in individuals with diagnosed iron overload (hemochromatosis), non-iron deficiency anemia, severe hepatic impairment, or certain acute or chronic infections. Furthermore, individuals with a history of asthma or significant allergies are noted to have an increased risk of hypersensitivity reactions. For pregnant individuals, severe maternal adverse reactions have been documented, which may cause fetal bradycardia.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Ferrum Hausmann, typically resulting from an excessive dose or an overly rapid rate of infusion, is officially documented to present with several immediate and delayed manifestations.

Documented Manifestations and Severe Outcomes

Initial manifestations may include hypotension, dizziness, nausea, vomiting, and abdominal pain, progressing to signs of circulatory failure. The most severe and life-threatening outcomes officially documented in regulatory information include cardiovascular collapse, shock, cardiac arrest, respiratory arrest, and fatalities. Delayed systemic presentations may involve arthralgia (joint pain), myalgia (muscle aches), and fever.

Required Emergency Actions

Patients must seek immediate medical attention and contact emergency services upon suspicion of overdose or the onset of severe systemic symptoms. The infusion must be stopped immediately. Regulatory documentation mandates that resuscitation techniques and medications, such as Epinephrine, must be readily available during administration.

Management and Monitoring

For cases of acute iron intoxication, the specific chelating agent Deferoxamine is documented for use. Management is symptomatic and supportive, focused on maintaining blood pressure and fluid balance. Hospital monitoring is required for suspected overdose. Population-specific notes include the risk of Fetal bradycardia if administered to pregnant women and potential exacerbation of Rheumatoid Arthritis symptoms.

Therapeutic Uses of Ferrum Hausmann

What Ferrum Hausmann Treats: Main Uses and Benefits

The treatment is used in situations involving certain distressing symptoms related to systemic imbalance and physiological strain. The therapy is relevant when supportive symptom management is appropriate and commonly used when short-term symptomatic assistance is needed. This therapeutic approach is applied across domains where additional symptomatic support is needed, specifically for conditions involving episodic or fluctuating manifestations, or those marked by increased physiological stress.

The medicine helps address symptom clusters that interfere with daily comfort and supports patients during difficult episodes by easing distress. The treatment is commonly used across conditions presenting with acute episodes, which may include situations requiring temporary assistance in symptom stabilization, and scenarios where symptoms become momentarily overwhelming. The treatment provides support that helps ease the overall symptom burden and contributes to improved comfort.

“The treatment is applied in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: May assist with Physical Discomfort and Functional Strain

Eligibility and Restrictions for Use

Official Population Eligibility Status

Eligibility for Ferrum Hausmann (Iron Dextran) is defined by regulatory documents based on two primary factors: the necessity for parenteral iron and the absence of prohibited medical conditions.

Populations Allowed and Restricted

Eligibility: Restricted to adult and pediatric patients (age 4 months and older) with documented iron deficiency anemia who have demonstrated intolerance to oral iron or an unsatisfactory response to it.
Absolute Contraindications: The medicine is strictly contraindicated in individuals with known hypersensitivity to iron dextran, evidence of iron overload (e.g., hemochromatosis), and anemias not caused by iron deficiency. Use must be avoided during the acute phase of systemic or infectious kidney disease.

Age and Condition Limitations

Age: Use is not recommended for infants under 4 months of age (US labeling). Specific EU labeling also advises against use in children under 14 years.
Caution Required: Use requires caution and close monitoring in patients with serious impairment of liver function, pre-existing cardiovascular disease, or a history of significant allergies, asthma, or inflammatory conditions (e.g., rheumatoid arthritis).
Pregnancy/Lactation: Use during pregnancy is conditional, permitted only if the potential benefit justifies the potential risk to the fetus. Caution is advised for use in nursing women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Iron (III) Hydroxide Dextran Complex, administered as an injection, is distinctly documented in official regulatory sources, focusing on mandatory prohibitions and altered risks with co-administered substances.

Formal Interaction Classifications

Classification Type	Interacting Substance/Class	Official Regulatory Statement
Contraindicated Combination	Dimercaprol (Chelating Agent)	Must be avoided or is formally prohibited from co-administration.
Pharmacodynamic Risk	Angiotensin-Converting Enzyme (ACE) Inhibitors	Co-administration may increase the documented risk for anaphylactic-type reactions.
Timing-Based Restriction	Oral Iron Preparations	Oral iron therapy should not be started earlier than 5 days after the last injection.

Procedural and Monitoring Constraints

The administration of the parenteral iron complex can interfere with laboratory testing. Specifically, the injection renders colorimetric serum iron assays not meaningful for up to three weeks following administration, impacting the accuracy of diagnostic monitoring. Furthermore, the presence of the injectable iron actively reduces the absorption of oral iron preparations, which is the basis for the mandatory timing separation required by regulatory labels. Therefore, all oral iron products must be discontinued prior to the start of this therapy.

Mechanism of Action

The mechanism of Iron(III) Hydroxide Dextran Complex is defined by its two-stage action: controlled delivery and substrate utilization, which together affect the body's capacity for oxygen transport. The drug's mechanism initiates with the endocytosis (uptake) of the stable iron complex by macrophages of the Reticuloendothelial System (RES). This controlled clearance mechanism, which separates the iron from its dextran shell in the lysosomes, leads to the slow and gradual release of the iron core, limiting the concentration of free, unbound iron ions in the systemic circulation. Once processed, the iron is mobilized and immediately bound to transferrin for transit to the bone marrow. This essential substrate delivery provides the necessary iron for the final steps of hemoglobin synthesis, which contributes to the formation of O2-carrying molecules in the blood. The rate of iron release and mobilization is regulated by the small peptide hormone hepcidin, which can internalize the iron exporter ferroportin on the macrophage surface. High hepcidin levels can trap iron within the RES cells, functionally blocking its final release into the plasma and reducing the subsequent systemic iron delivery.

Dosage and Administration Information

Administration Methods

Ferrum Hausmann is available in various oral formulations, including drops, syrups, and chewable tablets. The method of administration depends on the specific form prescribed.

Oral Drops and Syrup

The liquid forms can be mixed with fruit or vegetable juices. They may also be mixed with infant formula or other soft foods. A slight discoloration of the liquid or food does not affect the efficacy of the medication or the taste of the mixture.

Chewable Tablets

Chewable tablets can be chewed thoroughly or swallowed whole. They are designed to be taken during or immediately after a meal to support integration into a daily routine.

Duration of Use

Iron supplementation typically continues for several months. The duration is generally divided into two phases: the initial period to reach target hemoglobin levels, followed by a secondary period to replenish the body's iron stores. The total length of use is determined by clinical progress and the stabilization of iron parameters in the body.

Handling and Storage

To maintain the stability of the medication, it should be stored in its original packaging. The containers should be kept tightly closed when not in use and stored at room temperature, protected from direct sunlight and excessive heat.

Recent Clinical Evidence

Research evidence / Overview of studies for Ferrum Hausmann

The most established research base for Iron Dextran comes from studies focused on its core context: Severe Iron Deficiency Anemia (IDA). This was observed in numerous short-term Randomized Controlled Trials (RCTs) and aggregated in larger meta-analyses. Researchers primarily examined key blood markers like Hemoglobin (Hb) concentration and iron storage markers such as Ferritin and Transferrin Saturation (TSAT). These trials included adult patients diagnosed with severe IDA, especially those who could not tolerate or adequately absorb oral iron supplements.

Research highlights changes measured in these key blood biomarkers over the defined study period, which was typically short-term, often up to 12 weeks. Studies report how the levels of these blood markers evolved in the observed populations. Some trials described patterns related to the need for blood transfusions in patients across the studied groups. These findings contribute to the broader evidence landscape regarding iron status.

Evidence in Specific Patient Contexts

Research has also explored the use of Iron Dextran within specific medical contexts.

Research on Anemia in Chronic Kidney Disease

Studies were conducted during periods of increased symptom activity in patients with Chronic Kidney Disease (CKD). This research often involved controlled trials focusing on adults with CKD who are receiving therapy to stimulate red blood cell production (Erythropoiesis-Stimulating Agents, or ESAs). Researchers monitored changes in Hemoglobin and iron storage parameters and tracked patterns related to the required dosage of ESA medications. Findings indicate that this management strategy was observed in some studies that examined the measurements of target iron levels as defined by clinical protocols. Research data for certain groups remain limited, and because many of these patients were concurrently receiving ESA therapy, the evidence primarily describes observed patterns within this specific, medically-managed population, where the confounding effect of concomitant ESA use makes isolated attribution difficult.

Key Studies & References

Iron Dextran Injection: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Ferrum Hausmann (FAQ)

Q: Does Ferrum Hausmann cause black stools?

Black or dark stools are a common, non-serious effect when taking iron supplements orally because of unabsorbed iron passing through the digestive system. Since this medicine is administered by injection and bypasses the digestive tract, this specific effect is not commonly listed in the official product information for the injectable form.

Q: How long does it usually take to feel better after starting Ferrum Hausmann?

Official research and regulatory summaries do not specify a timeline for subjective, patient-reported outcomes like 'feeling better.' Instead, they focus on the time needed to see measurable improvements in key blood markers, such as hemoglobin and ferritin levels. These improvements are typically monitored by a healthcare professional; the observed changes in blood markers can take several weeks.

Q: Is it okay to drink coffee or tea while taking Ferrum Hausmann?

For oral iron, coffee and tea can interfere with absorption in the digestive tract. Since Ferrum Hausmann is administered by injection, it bypasses the digestive system entirely. Official regulatory documentation does not list coffee or tea as a relevant interaction for the injectable formulation.

Q: What happens if I miss a dose of Ferrum Hausmann?

Official patient instructions advise immediately contacting the healthcare provider for a revised schedule if a dose is missed. Because the necessary amount of medicine is calculated precisely, the dose should not be doubled.

Q: What if I'm already taking multivitamins? Can I still take Ferrum Hausmann?

Official documents caution against taking other products that contain iron, including oral iron preparations. Multivitamins often contain iron, and co-administration warrants discussion with a healthcare provider to prevent the risk of iron overload.

Q: Is Ferrum Hausmann commonly used for tiredness or fatigue?

The medicine is formally indicated for the treatment of Iron Deficiency Anemia (IDA). Tiredness and fatigue are recognized, common symptoms of IDA. The official product information indicates the medicine is used to treat IDA. As IDA is corrected, associated symptoms like tiredness and fatigue may improve.

Q: Does Ferrum Hausmann affect blood pressure?

Yes, official documentation lists hypotension (low blood pressure) as a documented adverse reaction. Due to the possibility of low blood pressure, regulatory documents emphasize monitoring during administration.

Q: Can Ferrum Hausmann cause constipation?

Constipation is a very common side effect of many oral iron supplements. However, for the injectable form, constipation is not commonly listed as a frequent adverse reaction in the official prescribing information, which lists a range of other gastrointestinal effects.

Q: Is Ferrum Hausmann suitable for vegetarians or vegans?

The active ingredient is a synthetic complex of iron and dextran. Suitability for vegetarian or vegan diets generally depends on the inactive ingredients (excipients) used in the formulation. This information can be confirmed by referring to the official composition data.

Q: Does the time of day matter when taking Ferrum Hausmann?

The regulatory instructions defining use focus on the total iron dose required, the maximum daily dose, and the rate of infusion. There is no official statement requiring that the medicine be administered at a specific time of day for efficacy.

Q: Can Ferrum Hausmann be used for heavy menstrual bleeding?

The official indication for the medicine is to treat Iron Deficiency Anemia (IDA). Heavy menstrual bleeding (menorrhagia) is a major, common medical cause of IDA, making this an indicated treatment context for the resulting iron deficiency.

Q: Does taking Ferrum Hausmann affect sleep?

Official side effect lists do not explicitly mention effects on sleep patterns. However, documented systemic side effects, such as developing a headache, fever, or chills, are conditions that have the potential to indirectly disrupt rest.

Q: Is it normal to have a metallic taste after taking Ferrum Hausmann?

Yes, official regulatory labeling lists an altered taste or metallic taste as a documented adverse reaction. This is generally considered an uncommon, temporary side effect.

Q: Can Ferrum Hausmann be taken with antacids?

Antacids primarily work by interfering with the absorption of oral iron in the digestive system. Since this product is an injection, regulatory documents do not typically list antacids as a relevant interaction.

Q: What are the most common reasons someone might stop taking Ferrum Hausmann?

The primary scheduled reason for stopping therapy is reaching the Total Iron Replacement Dose calculated by the prescribing physician. A non-scheduled reason for immediate discontinuation is the occurrence of a severe adverse event, such as a hypersensitivity or anaphylactic reaction.

Q: Are there any known long-term side effects associated with Ferrum Hausmann?

The primary clinical evidence supporting the use of this medicine is based on short-term studies, often lasting up to 12 weeks. Official adverse events lists do not generally distinguish effects that occur specifically over a long-term period.

Q: Can Ferrum Hausmann be used in elderly patients?

Adult patients are generally eligible for this medicine. Regulatory documents may include a general caution to use extra monitoring for elderly or debilitated patients, as they may be at an increased risk of adverse reactions.

Q: Are there documented cases of overdose with Ferrum Hausmann?

Official product information includes a section on Overdosage that outlines the risk of acute massive iron overload and the protocol for therapeutic intervention.

Q: Can Ferrum Hausmann be taken alongside calcium supplements?

Calcium supplements are known to interfere with the absorption of oral iron. Since this product is an injection administered directly into the body, regulatory labels generally do not list calcium supplements as a relevant interaction.

Q: Does Ferrum Hausmann affect my ability to drive or operate machinery?

Due to the potential for side effects like dizziness, official warnings advise patients to observe their individual reaction to the medicine before driving or operating machinery.

How should Ferrum Hausmann be stored and disposed of?

Storage and Disposal of Ferrum Hausmann Solution for Injection

The storage and handling of Ferrum Hausmann solution for injection (Iron Dextran) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

Storage and Stability Constraints

Freezing is Prohibited: The product must not be frozen and generally does not require any special temperature conditions for the unopened vial.
Single-Use and Inspection: The injection is for single use only. Before use, the container must be visually inspected, and only a sediment-free, homogeneous solution should be administered.
Stability After Dilution: From a microbiological standpoint, the solution should be used immediately after opening. Chemical stability has been demonstrated for 24 hours following dilution, provided it is stored at 25 C or 2 C to 8 C.